Evidence map›Paper›PMID 40924120›Full record

GuidelineStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2025

Modern approaches to radiotherapy in primary cutaneous lymphomas: insights and recommendations from the DEGRO dermato-oncology working group.

Khaled Elsayad, Dora Correia, Ulrike Theiß, Andrea Baehr, Angela Besserer, Oliver Micke, Burkhard Greve, Cora Waldstein, Stefanie Corradini, Daniel Habermehl and 4 more

Abstract readPractice Guideline
In one paragraph

Guideline in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Khaled ElsayadDepartment of Radiation Oncology, Philipps-University Marburg, Marburg, Germany. khaled.elsayad@uni-marburg.de.ORCID 0000-0001-9303-7336
Dora CorreiaDepartment of Radiation Oncology, Cantonal Hospital Aarau, Aarau, Aargau, Switzerland.
Ulrike TheißDepartment of Radiation Oncology, Philipps-University Marburg, Marburg, Germany.
Andrea BaehrDepartment of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Angela BessererDepartment of Radiation Oncology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Oliver MickeDepartment of Radiation Oncology, Franziskus Hospital Bielefeld, Bielefeld, Germany.
Burkhard GreveDepartment of Radiation Oncology, University Hospital of Münster, Münster, Germany.
Cora WaldsteinDepartment of Radiation Oncology, Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria.
Stefanie CorradiniDepartment of Radiation Oncology, LMU University of Munich, 81388, Munich, Germany.
Daniel HabermehlDepartment of Radiation Oncology, Justus-Liebig-University, UKGM Giessen, Giessen, Germany.
Laila KönigDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Kathrin HeringDepartment of Radiation Oncology, University of Leipzig Medical Center, Leipzig, Germany.
Sebastian AdebergDepartment of Radiation Oncology, Philipps-University Marburg, Marburg, Germany.
Hans Theodor EichDepartment of Radiation Oncology, University Hospital of Münster, Münster, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The growing use of reduced-dose radiotherapy in patients with primary cutaneous lymphoma is a promising development. Nevertheless, the absence of controlled clinical trials to ascertain standardized doses for each specific type constitutes a significant impediment to the advancement of this field. This expert opinion strongly advocates for advancements in radiation oncology practice that address the unique complexities of primary cutaneous lymphoma. By refining our methodologies, we can optimize patient care and outcomes in this dynamic field.

Indexed as

LymphomaLymphoma, T-Cell, CutaneousRadiation OncologySkin NeoplasmsGermanyHumansRadiotherapy DosageIMRTOvertreatmentQuality of lifeShared decision-makingS-MISR-Register

Identifiers

PMID40924120
PMCPMC12701040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.